Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor

  • Technology appraisal guidance
  • TA670
  • Published: 
Download guidance (PDF)

2 Information about brigatinib

Marketing authorisation indication

2.1

Brigatinib (Alunbrig, Takeda) has a marketing authorisation for 'the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) previously not treated with an ALK inhibitor'.

Dosage in the marketing authorisation

Price

2.3

The list price of brigatinib is £4,900.00 (excluding VAT; BNF accessed November 2020) for the:

  • starter pack (7 tablets at 90 mg plus 21 tablets at 180 mg)

  • 28‑tablet pack at 180 mg.

    The company has a commercial arrangement. This makes brigatinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.